Biocartis Group NV 2022 AR2
The report highlights Biocartis' operational and financial performance in 2022, showcasing a 30% growth in core oncology revenues and a doubling of the product gross margin to 34%. The company expanded its global footprint with the regulatory approval of the Idylla instrument in China and the Idylla MSI Test in Japan. Biocartis also introduced its new Idylla FLEX technology, launching the first assay developed with it. Additionally, the company successfully completed a comprehensive recapitalization, securing EUR 66 million in gross proceeds to support future growth.
Company: Biocartis Group NV
Sector: Manufacturing
Country: Belgium
Year: 2022
Type: AR2
Pages: 196
Back to company
Biocartis Group NV
Annual Report
The report highlights Biocartis' operational and financial performance in 2022, showcasing a 30% growth in core oncology revenues and a doubling of the product gross margin to 34%. The company expanded its global footprint with the regulatory approval of the Idylla instrument in China and the Idylla MSI Test in Japan. Biocartis also introduced its new Idylla FLEX technology, launching the first assay developed with it. Additionally, the company successfully completed a comprehensive recapitalization, securing EUR 66 million in gross proceeds to support future growth.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees